Letters sent to healthcare professionals in November 2015

In November, letters were sent regarding thalidomide, mycophenolate mofetil, nicorandil, InductOs, and dimethyl fumarate

From:
Medicines and Healthcare products Regulatory Agency
Published
14 December 2015
Last updated
14 December 2015 鈥� See all updates
Therapeutic area:
Cancer, Cardiovascular disease and lipidology, GI, hepatology and pancreatic disorders, Haematology and oncology, Immunosuppression and transplantation, Neurology and Obstetrics, gynaecology and fertility

A summary of letters sent to healthcare professionals in November 2015 to inform of safety for:

  • Thalidomide (): reduced starting dose in patients older than age 75 years (see also this month鈥檚 article)
  • Mycophenolate mofetil (): pregnancy-prevention advice (see also this month鈥檚 article)
  • Nicorandil (): second-line treatment for angina; risk of progressive ulceration
  • .: supply shortage
  • Dimethyl fumarate (): new measures to minimise the risk of progressive multifocal leukoencephalopathy

Updates to this page

Published 14 December 2015
Last updated 14 December 2015 show all updates

  1. Letters sent to healthcare professionals in November 2015

  2. First published.